EP0973737A4 - Synthese efficace d'un mediateur chiral - Google Patents

Synthese efficace d'un mediateur chiral

Info

Publication number
EP0973737A4
EP0973737A4 EP98903459A EP98903459A EP0973737A4 EP 0973737 A4 EP0973737 A4 EP 0973737A4 EP 98903459 A EP98903459 A EP 98903459A EP 98903459 A EP98903459 A EP 98903459A EP 0973737 A4 EP0973737 A4 EP 0973737A4
Authority
EP
European Patent Office
Prior art keywords
compound
recited
formula
phenyl
enantiomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98903459A
Other languages
German (de)
English (en)
Other versions
EP0973737A1 (fr
Inventor
Cheng Yi Chen
Feng Xu
Richard D Tillyer
Dalian Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9704194.1A external-priority patent/GB9704194D0/en
Priority claimed from GBGB9710393.1A external-priority patent/GB9710393D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0973737A1 publication Critical patent/EP0973737A1/fr
Publication of EP0973737A4 publication Critical patent/EP0973737A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/14—Aza-phenalenes, e.g. 1,8-naphthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/092—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings with aromatic radicals attached to the chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Definitions

  • the instant invention discloses an efficient method for the quantitative preparation and isolation of the enantiomers of the compound of formula I I
  • the present invention concerns a novel process for the preparation of a compound of formula I
  • the present invention also concerns compounds of Formula I as chiral mediators useful in enantioselective synthesis.
  • An example of a compound of Formula I is (1R,2S)-N- pyrrolidinyl norephedrine, which is a chiral mediator used in an enantioselective addition reaction.
  • the preparation of [R-(R*,S*)]- ⁇ - methyl- - ⁇ henyl-1-pyrrolidineethanol in quantitative yield was accomplished by alkylation of (lR,2S)-(-)-norephedrine with 1,4- dibromobutane in toluene using NaHC ⁇ 3 as base.
  • the instant invention relates to a method for the preparation of a compound of Formula I
  • n 1, 2, or 3;
  • n 0, or 1 ;
  • R! is: H, phenyl, or Cl-C6-alkyl, unsubstituted or substituted with Cl-C6-alkoxy;
  • R2 is: H, Cl-C6-alkyl, or
  • R 3 is: H, C ⁇ -C6-alkyl, or phenyl
  • R4 is: H, except that Rl and R4 can represent a carbon carbon bond, when t is lor 2, or — (CH2)s — » when t is 0;
  • step (a) wherein the base is selected from the group consisting of: Li2C ⁇ 3, Na2C ⁇ 3, K2CO3, L1HCO3, NaHC ⁇ 3, KHCO3, LiOH, NaOH, and KOH.
  • step (a) wherein the solvent is selected from the group consisting of: toluene, heptane, n- butanol, methylcyclohexane, and tetrahydrofuran.
  • step (a) wherein (1R,2S)- (-)-norephedrine to alkylating agent ratio is about a 1 to 1.1 ratio.
  • step (a) wherein the dihalide to base ratio is about a 1 to 2 ratio.
  • step (a) wherein the base is preferably KHCO3, NaHC ⁇ 3, K2CO3, and Na2C ⁇ 3.
  • step (a) wherein the solvent system is toluene.
  • step (a) wherein the reaction temperature is about 105° to about 118°C.
  • step (a) wherein the reaction time is about 18 to about 24 hours.
  • step (a) wherein (1R,2S)- norephedrine to 1 ,4-dibromobutane ratio is about a 1 to 1.1 ratio.
  • step (a) wherein the 1,4- dibromobutane to NaHC ⁇ 3 is about a 1 to 2 ratio.
  • step (a) wherein the reaction temperature is about 105° to about 118°C.
  • ⁇ / ⁇ represents a six-membered ring, unsaturated or saturated, optionally substituted with one or two heteroatoms selected from N, O, or S, optionally substituted with Cl-C6-alkyl;
  • n 1, 2, or 3;
  • n 0, or 1;
  • t 0, 1, or 2;
  • s 1 or 2;
  • R! is: H, phenyl, or Cl-C6-alkyl, unsubstituted or substituted with Cl-C6-alkoxy;
  • R is: H, Cl-C6-alkyl, or
  • R3 is: H, Cl-C6-alkyl, or phenyl
  • R4 is: H, except that Rl and R4 can represent a carbon carbon bond, when t is lor 2, or — (CH2)s — , when t is 0,
  • Rl is H or CH3, that A cannot represent
  • A cannot represent — (CHR3) n — , when n is 2, and R3 is H, as a free base or an acid salt thereof.
  • An acid salt such as a salt of an organic acid or inorganic acid.
  • organic acids capable of forming an acid salt include but are not limited to: citric acid, acetic acid, trifluoroacetic acid, maleic acid, methanesulfonic acid, p-toluenesulfonic acid, formic acid, and benzoic acid.
  • inorganic acids capable of forming an acid salt include but are not limited to: HC1, HBr, H3PO4 and H2SO4.
  • A represents:
  • -/ 5 ⁇ represents: a five-membered ring, unsaturated or saturated, optionally substituted with one or two heteroatoms selected from N, O, or S, optionally substituted with Cl-C6-alkyl;
  • n 1, 2, or 3;
  • n 0, or 1 ;
  • t 0, 1, or 2;
  • s 1 or 2;
  • R! is: H, phenyl, or Cl-C6-alkyl, unsubstituted or substituted with Cl-C6-alkoxy;
  • R 2 is: H, Cl-C6-alkyl, or
  • R 3 is: H, Cl-C6-alkyl, or phenyl
  • R4 is: H, except that Rl and R4 can represent a carbon carbon bond, when t is lor 2, or — (CH2)s — , when t is 0;
  • step (e) wherein the solvent is selected from the group consisting of: toluene, heptane, n-butanol, methylcyclohexane and tetrahydrofuran.
  • step (e) wherein the aqueous acid solution is selected from the group consisting of: an aqueous inorganic acid solution and an aqueous organic acid solution.
  • step (a) wherein aminoalcohol compound to dihalide ratio is about 1 to about 1.1 ratio.
  • step (a) wherein the dihalide to base ratio is about 1 to about 2 ratio.
  • step (a) wherein the base is selected from the group consisting of: KHCO3, NaHC ⁇ 3, K2CO3, and Na2C ⁇ 3.
  • aqueous acid solution is an aqueous inorganic acid solution selected from the group consisting of: HC1, HBr, H3PO4 and H2SO4.
  • aqueous acid solution is an aqueous organic acid solution selected from the group consisting of: citric acid, acetic acid, trifluoroacetic acid, maleic acid, methylsulfonic acid, p-toluenesulfonic acid, formic acid, and benzoic acid.
  • step (a) wherein the reaction temperature is about 105° to about 118°C.
  • step (a) wherein the reaction time is about 18 to about 24 hours.
  • step (e) wherein the aqueous acid solution is citric acid.
  • step (g) wherein the base is selected from the group consisting of: aqueous LiOH, KOH and NaOH.
  • the compound of Formula I is selected from the group consisting of:
  • [R-(R*,S*)]- ⁇ -methyl- ⁇ -phenyl-l-py ⁇ olidineethanol also referred to as (1R,2S )- ⁇ -pyrrolidinylnorephedrine
  • (1R,2S )- ⁇ -pyrrolidinylnorephedrine is an important chiral mediator for the enantioselective addition of an acetylide to a prochiral ketone.
  • alkylating agent useful in this method are: 1,3-dibromopropane, 1 ,4-dibromobutane, 1,5-dibromo ⁇ entane, (2- bromomethyl)benzylbromide, 2-(2-bromoethyl)benzylbromide, 1,2- di(bromomethyl)naphthalene, 2,3-di(bromomethyl)naphthalene, 1,8- di(bromomethyl)naphthalene, etc.
  • heterocyclic alkylating agents are: [2,3-di(bromomethyl)]pyridine, [3,4- di(bromomethyl)]-pyridine, 2-(2-bromoethyl)-3-bromomethylpyridine, 3-(2-bromoethyl)-2-bromomethylpyridine, 3-(2-bromoethyl)-4- bromomethylpyridine, 4-(2-bromoethyl)-3-bromomethylpyridine, 3-(2- bromoethyl)-4-bromomethyl-pyridine, etc.
  • chloride, iodide, tosylate, mesylate and triflate analogs of the aforementioned alkylating agents are: Li2C ⁇ 3, Na2C ⁇ 3,
  • the solvent systems useful in this method are: toluene, heptane, n-butanol, tetrahydrofuran.
  • the preferred base-solvent system was NaHC03- toluene, which allowed for the isolation of the chiral mediator in crystalline form in qualitative yield.
  • the actual compound used in the chiral addition reaction is the free base, which is generated in situ prior to use in the addition reaction.
  • Step A Preparation of [R-(R*,S*)]- ⁇ -methyl- ⁇ -phenyl-l- pyrrolidineethanol Under nitrogen, to a 22 L three-necked round bottom flask equipped with a mechanical stirrer, a condenser with Dean-Stark trap and a thermocouple was charged with toluene (8 L), (1R,2S )-(-)- norephedrine (1.512 kg, 10 mol), 1 ,4-dibromobutane (2.375 kg, 11
  • HPLC conditions HPLC Column: 4.6 mm x 25 cm Inertsil phenyl Eluent A: MeCN; Eluent B: pH 6.0 phosphate buffer, 15 mM (8.28 g NaH2P ⁇ 4-H2 ⁇ and 0.8 mL Et3N in 4 L HPLC grade water); Gradient: 14% A kept for 5 min then changed to 44% A over 11 min and kept this ratio for another 6min; Injection: 20 ⁇ L; Flow rate: 1.5 mL/min; Detection: 210 nm; Temperature: 23 °C; and Retention Times: Sodium bromide: 1.8 min; Norephedrine: 5.0 min; Product: 12.0 min; Toluene: 22.5 min. 4.
  • the main purpose here is to remove most of the water in the toluene solution because the water in toluene solution would interfere the HC1 salt formation, lowering the recovery of the salt product.
  • Step B Preparation of [R-(R*,S*)]- ⁇ -methyl- ⁇ -phenyl-l- pyrrolidineethanol hydrochloride
  • the batch volume of the organic layer from Step A was then adjusted to 10 L with toluene and cooled to 10-15°C with ice-water bath.
  • HC1 in IPA (2.56 L, 4.3 N) was added to the toluene solution slowly over a period of about 50 minutes, keeping the batch temperature below 25°C (note 6).
  • the batch was aged at ambient temperature for 1 h and isopropyl alcohol was removed by azeotropic distillation (Note 7).
  • the batch was flushed with toluene (2x2 L) until the concentration of the product in supernatant was less than 3 g/L.
  • the batch was then cooled to 15°C and aged at this temperature for 1 h.
  • the HC1 salt was isolated by filtration and the wet cake was washed with toluene (2x2.5 L). The product loss in combined filtrate and wash was less than 1%.
  • Step C Isolation of [R-(R*,S*)]- ⁇ -methyl- ⁇ -phenyl-l- pyrrolidineethanol
  • HPLC sample preparation 50 ⁇ L filtered clear reaction solution (Whatman syringe filter 0.45 ⁇ M PTFE) was dissolved in 50/50 MeCN/water to 50 mL.
  • the ratio of the product to starting material norephedrine HPLC area percentage should be around 94.5:5.5 or higher.
  • the level of 1 ,4-dibromobutane (the ratio to product should be less than 0.8 mole%) could be determined by proton NMR or GC (GC method hasn't been developed yet).
  • the batch was cooled to ambient temperature, filtered through a sintered glass funnel to remove solid sodium bromide salt.
  • the wet cake was washed with 300 mL toluene.
  • the combined filtrate and wash was washed with D.I. water 2x400 mL.
  • the top organic layer was then concentrated on a rotavap to around 400 mL (1/3 of the original total volume).
  • Step B Preparation of [R-(R*,S*)]- ⁇ -methyl- -phenyl-l- pyrrolidineethanol Hydrochloride
  • the batch was then transferred back to the reaction flask and adjusted to 800 mL with toluene. It was cooled to 10-15°C with ice- water bath and HCl in IPA (260 mL, 4.5 N) was added slowly in 30 min while kept the batch temperature below 25°C. The batch was aged at
  • Step C Isolation of [R-(R*,S*)]- ⁇ -methyl- ⁇ - ⁇ henyl-l- pyrrolidineethanol
  • the wet cake was transferred to a separatory funnel, 800 mL toluene and 700 mL 1.5 N NaOH were added (no obvious exothermic observed). Two phases were mixed well and layers were separated. The aqueous layer (pH>12) was extracted with toluene 2x500 mL. The combined organic layer was concentrated on a rotavap and flushed with toluene 1x500 mL. The final batch volume was adjusted to about 500 mL. The final solution gave [R-(R*,S*)]- ⁇ -methyl- ⁇ -phenyl- 1 -pyrrolidineethanol (212 g) in toluene as a light yellow solution (45wt%) with 95% yield.
  • HPLC Conditions Column: 4.6 mm x 25 cm Inertsil phenyl;
  • Eluent A MeCN
  • Eluent B pH6.0 phosphate buffer [15 mM (8.28 g NaH 2 P ⁇ 4-H2 ⁇ and 0.8 mL Et3N in 4 L HPLC grade water)];
  • the batch was cooled to ambient temperature, filtered through a sintered glass funnel to remove solid sodium bromide salt.
  • the wet cake was washed with 3 L toluene.
  • the combined filtrate and wash was washed with D.I. water 1 x 6 L (the product in aqueous layer loss was less than 1%).
  • the organic layer was transferred to a 50 L extractor and extracted with 30% aqueous citric acid solution at room temperature. The mixture was stirred for 15 min and the layers were separated. The aqueous layer was transferred back to the extractor which contained 10 L toluene. 50 w/w% NaOH (3.57 kg) was added slowly so that the temperature was kept below 30 °C. The mixture was stirred for 15 min and the layers were separated, (the pH of the aqueous layer was 12-12.5). The aqueous layer was extracted with toluene once (1x5 L). The aqueous layer was removed and combined organic layers were washed with D.I. water twice (2x5 L).
  • the washed organic layer was concentrated with vacuum and the batch volume was reduced to about 6-8 L.
  • the batch was then flushed with toluene 2x3 L.
  • the final batch volume was adjusted to about 5 L which gave the product (1.97 kg) in toluene as a light yellow solution (38 wt%) with 96% yield.
  • the solution KF was 80-100 ⁇ g/mL.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Lasers (AREA)

Abstract

La présente invention concerne un procédé efficace de préparation quantitative et d'isolement d'un composé de formule (I) ou de son énantiomère, lequel est un médiateur chiral utilisé dans une synthèse énantiosélective.
EP98903459A 1997-01-10 1998-01-06 Synthese efficace d'un mediateur chiral Withdrawn EP0973737A4 (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US3492697P 1997-01-10 1997-01-10
US34926P 1997-01-10
GBGB9704194.1A GB9704194D0 (en) 1997-02-28 1997-02-28 Efficient synthesis of a chiral mediator
GB9704194 1997-02-28
US4202197P 1997-04-17 1997-04-17
US42021P 1997-04-17
US4516797P 1997-04-30 1997-04-30
US45167P 1997-04-30
GB9710393 1997-05-20
GBGB9710393.1A GB9710393D0 (en) 1997-05-20 1997-05-20 Efficient synthesis of a chiral mediator
PCT/US1998/000578 WO1998030540A1 (fr) 1997-01-10 1998-01-06 Synthese efficace d'un mediateur chiral

Publications (2)

Publication Number Publication Date
EP0973737A1 EP0973737A1 (fr) 2000-01-26
EP0973737A4 true EP0973737A4 (fr) 2000-04-26

Family

ID=27517397

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98903459A Withdrawn EP0973737A4 (fr) 1997-01-10 1998-01-06 Synthese efficace d'un mediateur chiral

Country Status (5)

Country Link
EP (1) EP0973737A4 (fr)
JP (1) JP2000507970A (fr)
AU (1) AU732430B2 (fr)
CA (1) CA2276074A1 (fr)
WO (1) WO1998030540A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015926A (en) * 1997-05-16 2000-01-18 Merck & Co., Inc. Efficient enantioselective addition reaction using an organozinc reagent
DE10019879A1 (de) * 2000-04-20 2001-10-25 Degussa Verfahren zur Herstellung von 2,5-Diketopiperazinen, neue 2,5-Diketopiperazine und deren Verwendung
EP2417097A2 (fr) 2009-04-09 2012-02-15 Lonza Ltd. Procede autocatalytique pour la synthese d'alcools propargyliques chiraux
WO2010115639A1 (fr) 2009-04-09 2010-10-14 Lonza Ltd Procede pour la synthese d'un alcool propargylique
EP2447255A1 (fr) 2010-10-14 2012-05-02 Lonza Ltd. Processus de synthèse de carbamates cycliques
EP2447247A1 (fr) 2010-10-14 2012-05-02 Lonza Ltd. Processus pour la synthèse d'alcools propargyliques chiraux

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030339A1 (fr) * 1995-03-31 1996-10-03 Pfizer Inc. Composes d'acide pyrrolidinyl-hydroxamique et leur procede de production
WO1996037457A1 (fr) * 1995-05-25 1996-11-28 Merck & Co., Inc. Synthese asymetrique de (-) 6-chloro-4-cyclopropyle-ethynyle-4-trifluoromethyle-1,4-dihydro-2h-3,1-benzoxazin-2-one

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3028378A (en) * 1962-04-03 Pharmacologically active compounds
BE481067A (fr) * 1947-05-23
US2552502A (en) * 1947-09-11 1951-05-08 Upjohn Co Beta-(pyrrolidyl-1)-propanol-2
US2723269A (en) * 1949-11-03 1955-11-08 American Cyanamid Co Piperidino tertiary amino alcohols
US2975193A (en) * 1959-06-18 1961-03-14 Parke Davis & Co Organic amine compounds and method of obtaining the same
US3468893A (en) * 1966-03-14 1969-09-23 Ciba Geigy Corp 1-substituted-diphenyl-azacycloalkenes
US3754003A (en) * 1971-07-08 1973-08-21 A Pedrazzoli Tetramethyl pyrrolidine derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030339A1 (fr) * 1995-03-31 1996-10-03 Pfizer Inc. Composes d'acide pyrrolidinyl-hydroxamique et leur procede de production
WO1996037457A1 (fr) * 1995-05-25 1996-11-28 Merck & Co., Inc. Synthese asymetrique de (-) 6-chloro-4-cyclopropyle-ethynyle-4-trifluoromethyle-1,4-dihydro-2h-3,1-benzoxazin-2-one

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AZIZOV A M ET AL: "Complete alkylation of 2-aminoethanol in the presence of sodium hydroxide", AZERB. KHIM. ZH. (AZKZAU,00052531);1985; (6); PP.61-5, Azerb. Inzh.-Stroit. Inst.;Baku; USSR (SU), XP002131296 *
BROWN E ET AL: "Asymmetric reductions of ketones using lithium aluminum hydride modified with N,N-dialkyl derivatives of (R)-(-)-2-aminobutan-1-ol", TETRAHEDRON: ASYMMETRY (TASYE3,09574166);1991; VOL.2 (5); PP.339-42, Fac. Sci.;Lab. Synth. Org.; Le Mans; 72017; Fr. (FR), XP000872930 *
PIERCE M E ET AL: "Practical Asymmetric Synthesis of Efavirenz (DMP 266), an HIV-1 Reverse Transcriptase Inhibitor", J. ORG. CHEM. (JOCEAH,00223263);1998; VOL.63 (23); PP.8536-8543, The DuPont Pharmaceuticals Company;Chemical Process R&D Department Process Research Facility; Deepwater; 08023-0999; NJ; USA (US), XP000881116 *
See also references of WO9830540A1 *

Also Published As

Publication number Publication date
AU6022598A (en) 1998-08-03
EP0973737A1 (fr) 2000-01-26
WO1998030540A1 (fr) 1998-07-16
JP2000507970A (ja) 2000-06-27
AU732430B2 (en) 2001-04-26
CA2276074A1 (fr) 1998-07-16

Similar Documents

Publication Publication Date Title
JP5632279B2 (ja) 塩酸イバブラジンの調製方法及びポリモルフ
KR20100027025A (ko) （3，4­디메톡시­바이시클로〔4．2．0〕옥타­1，3，5­트리엔­7­일）니트릴의 거울상이성질체의 분리 방법 및 이바브라딘의 합성에서의 적용
WO2006003471A2 (fr) Nouveau procede
US5925789A (en) Asymmetric synthesis of benzoxazinones
KR20000064735A (ko) R-α-프로필-피페로닐 아민 및 그의 유사체의 신규 비대칭 합성 방법
EP0973737A1 (fr) Synthese efficace d'un mediateur chiral
RU2167868C2 (ru) Способ получения норбензоморфана
EP3207041A1 (fr) Procédé amélioré de préparation de chlorhydrate de lurasidone
US5856492A (en) Efficient synthesis of a chiral mediator
EP0998470B1 (fr) Procede de preparation de derives amines d'alkyloxyfuranone, composes issus de ce procede et utilisation de ces composes
US20040102651A1 (en) Synthesis of 3-aminomethyl-1-propanol, a fluoxetine precursor
JP2022535112A (ja) ４－フェニル－５－アルコキシカルボニル－２－チアゾール－２－イル－１，４－ジヒドロピリミジン－６－イル］メチル］－３－オキソ－５，６，８，８ａ－テトラヒドロ－１Ｈ－イミダゾ［１，５－ａ］ピラジン－２－イル］－カルボン酸を調製するための代替方法
WO2015081920A1 (fr) Procédé de préparation de lurasidone et de son intermédiaire
RU2144026C1 (ru) Способ получения r(+)-1,2,3,6-тетрагидро-4-фенил-1-[(3-фенил-3-циклогексен-1-ил)метил]пирид ина или его фармацевтически приемлемых солей, промежуточные вещества и способы их получения
JPH09221472A (ja) α−シクロアルキルアルキル置換メタンアミン類の不斉合成方法
JP2002371060A (ja) 光学活性アミノピペリジン誘導体の製造方法
JP2019513805A (ja) Ｄｌ−４，４’−ビフェニルアラニンアルキルエステルからｄ−４，４’−ビフェニルアラニンアルキルエステルまたはｌ−４，４’−ビフェニルアラニンアルキルエステルを製造する方法
JP2999146B2 (ja) アミノケトン誘導体のラセミ化方法
AU2005273649B2 (en) Enantioselective synthesis of 13-oxotricyclo[8.2.1.0 3,8]trideca-3(8),4,6-triene-5-carboxylates
JP4441260B2 (ja) ４−アミノ−４−フェニルピペリジン類の製造方法
JPH0770070A (ja) 光学活性な１−（４−クロロピリジン−２−イル）−２−（ピリジン−２−イル）エチルアミンの製造法および中間体
KR20100022272A (ko) 신규한 ｓ-(-)-암로디핀 제조방법
US20090247581A1 (en) Organic Compounds
KR20200032281A (ko) 카보네이트를 이용한 시탈로프람 및 에스시탈로프람의 새로운 제조 방법
EP1233939A1 (fr) Procede relatif a l'elaboration d'acides alpha-hydroxy optiquement actifs, y compris leurs derives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990810

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07D 205/04 A, 7C 07D 209/44 B, 7C 07D 211/14 B, 7C 07D 221/04 B, 7C 07D 295/088 B, 7C 07D 295/092 B, 7C 07D 295/096 B, 7C 07D 295/08 B, 7C 07D 221/14 B

A4 Supplementary search report drawn up and despatched

Effective date: 20000315

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20010412

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020514